BEYONTTRA
Royalty Monetization$300 Million
JUN 2025
PRODUCTBEYONTTRA
Beyonttra (acoramidis) is a twice daily, oral, small-molecule, transthyretin (TTR) stabilizer indicated for the treatment of wild-type or variant transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM). ATTR-CM is a progressive disease caused by destabilization of TTR and subsequent accumulation of misfolded TTR protein in the myocardium. This leads to heart failure and, if left untreated, can ultimately result in death. Acoramidis was approved in the U.S. as Attruby by the FDA in November 2024 and in Europe as BEYONTTRA by the European Commission in February 2025.
Background
HealthCare Royalty acquired a portion of the royalties on European net sales of Beyonttra due to BridgeBio Pharma by Bayer AG, a leading marketer of cardiovascular products that holds the European commercial rights to the product. Healthcare Royalty was joined by Blue Owl in this royalty purchase, with Healthcare Royalty investing $200 million and Blue Owl contributing the remainder.
The transaction meaningfully extends BridgeBio’s cash runway, enabling the Company to accelerate the U.S. launch of acoramidis and to continue investing in its wholly-owned pipeline of development candidates targeting a range of genetic diseases.
Note: This transaction also appears in the Royalty Monetization section under Beyonttra.
News
JUNE 30, 2025
